Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Fractyl Health, Inc. (GUTS)
NASDAQ:GUTS
Holding GUTS?
Track your performance easily
Earnings Data
Report Date
Apr 07, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.44Last Year’s EPS
$0Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 12, 2024
|% Change Since: -18.93%
|Next Earnings Date:Apr 07, 2025
Earnings Call Sentiment|Neutral
The call highlighted significant progress in pivotal studies and FDA recognition, demonstrating strong potential for Fractyl's therapies in obesity and type 2 diabetes. However, financial challenges and the real-world limitations of GLP-1 drugs posed notable obstacles.Company Guidance
During the Q3 2024 earnings call for Fractyl Health, significant guidance and metrics were highlighted. The company reported a net loss of $23.2 million, compared to $15.7 million in the same period in 2023, primarily due to increased R&D expenses, which rose from $9.4 million to $19 million. This increase was attributed to progress in the REMAIN-1 and REVITALIZE-1 clinical studies and the Rejuva program. Selling, general, and administrative expenses were $4.8 million, up from $4.5 million in 2023. Fractyl's cash and cash equivalents stood at $84.7 million as of September 30, 2024, expected to fund operations into Q4 2025. Key clinical updates included the completion of patient enrollment for the midpoint analysis of the REMAIN-1 study, with results anticipated in Q2 2025, and upcoming REVEAL-1 data by year-end. The company also discussed its innovative approach in obesity and type 2 diabetes treatment, emphasizing the potential of its Revita and Rejuva platforms to meet unmet needs in durable weight maintenance and metabolic disease management.Enrollment Progress in Pivotal Studies
Successful enrollment in REMAIN-1 pivotal study for weight maintenance after GLP-1 discontinuation and the expanded protocol for the ReVITALIZE-1 pivotal study for Revita in type 2 diabetes.
Breakthrough Device Designation
Revita received breakthrough device designation from the FDA for weight maintenance after discontinuation of GLP-1-based drugs, marking it as a unique device in the obesity market.
Positive Clinical Data Presentation
Presented compelling weight maintenance data from Revita at medical meetings, showing 90% of participants lost weight 1 month after the procedure, with 84% maintaining weight loss for a full year.
Rejuva Platform Progress
Nominated Rejuva-002 for obesity treatment, expanding the platform's applications and showcasing potential for durable metabolic resets.
---
GUTS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
GUTS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 12, 2024 | $2.43 | $2.37 | -2.47% |
| Aug 14, 2024 | $2.23 | $2.35 | +5.38% |
| May 13, 2024 | $6.10 | $6.62 | +8.52% |
| Apr 01, 2024 | $7.40 | $7.45 | +0.68% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Fractyl Health, Inc. (GUTS) report earnings?
Fractyl Health, Inc. (GUTS) is schdueled to report earning on Apr 07, 2025, TBA Not Confirmed.
What is Fractyl Health, Inc. (GUTS) earnings time?
Fractyl Health, Inc. (GUTS) earnings time is at Apr 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is GUTS EPS forecast?
GUTS EPS forecast for the fiscal quarter 2024 (Q4) is -$0.44.
---